Common bean (*Phaseolus vulgaris* L.) $\alpha$-amylase inhibitors as safe nutraceutical strategy against diabetes and obesity: An update review

Stefania Peddio 1 | Alessandra Padiglia 2 | Faustina B. Cannea 2 | Roberto Crnjar 1 | Wissam Zam 3 | Javad Sharifi-Rad 4 | Antonio Rescigno 1 | Paolo Zucca 1

1Department of Biomedical Sciences (DiSB), Cittadella Universitaria di Monserrato, Cagliari, Italy
2Department of Life and Environmental Sciences (DiSVA), Cittadella Universitaria di Monserrato, Cagliari, Italy
3Department of Analytical and Food Chemistry, Faculty of Pharmacy, Al-Wadi International University, Tartous, Syria
4Facultad de Medicina, Universidad del Azuay, Cuenca, Ecuador

Correspondence
Antonio Rescigno and Paolo Zucca, Dipartimento di Scienze Biomediche (DiSB), Cittadella Universitaria di Monserrato, 09042 Monserrato, Cagliari, Italy.
Email: rescigno@unica.it and pzucca@unica.it

**Abstract**

Overweight and obesity are constantly increasing, not only in Western countries but also in low-middle-income ones. The decrease of both the intake of carbohydrates and their assimilation are among the main dietary strategies to counter these conditions. $\alpha$-Amylase, a key enzyme involved in the digestion of carbohydrates, is the target enzyme to reduce the absorption rate of carbohydrates. $\alpha$-Amylase inhibitors ($\alpha$-Als) can be found in plants. The common bean, *Phaseolus vulgaris* is of particular interest due to the presence of protein-based $\alpha$-Als which, through a protein–protein interaction, reduce the activity of this enzyme. Here we describe the nature of the various types of common bean seed extracts, the type of protein inhibitors they contain, reviewing the recent Literature about their molecular structure and mechanism of action. We also explore the existing evidence (clinical trials conducted on both animals and humans) supporting the potential benefits of this protein inhibitors from *P. vulgaris*, also highlighting the urgent need of further studies to confirm the clinical efficacy of the commercial products. This work could contribute to summarize the knowledge and application of *P. vulgaris* extract as a nutraceutical strategy for controlling unwanted weight gains, also highlighting the current limitations.

**KEYWORDS**
amylase inhibitor, bean, diabetes, obesity, *Phaseolus vulgaris*

1 | **INTRODUCTION**

Overweight and obesity are one of the major health concerns of our times, being considered the fifth leading risk for global deaths worldwide (The European Association for the Study of Obesity, 2021). According to WHO, more than 1.9 billion adults were overweight in 2016, and over 650 million of these were obese. Even among children and adolescents, obesity is a serious problem; over 340 million children and adolescents aged 5–19 were overweight or obese in 2016 with an increase of 14% from 1975 (WHO, 2021). It is estimated that globally there are more people obese than underweight in every region, except for some parts of sub-Saharan Africa and Asia.

The imbalance between energy expenditure and diet calorie intake has been identified as the cause of this condition, being mainly

**Abbreviations:** BMI, body mass index; GI, glycemic index; PHA, phytohemoagglutinins; PPA, porcine pancreatic $\alpha$-amylase; WL, weight loss; WM, weight maintenance; $\alpha$-AI, $\alpha$-amylase inhibitor.
caused by the decrease in physical activity and the shift toward diets rich in sugars and fats, and low in fibers and micronutrients (vitamins, minerals and so on) (Barrett & Udani, 2011).

Besides, overweight and obesity are related to many common health consequences, increasing risk for cardiovascular diseases, hypertension, type 2 diabetes (Meigs et al., 2006), dyslipidemia, sleep apnea, knee osteoarthritis (Raud et al., 2020), and certain types of cancer (Taroeno-Hariadi, Hardianti, Sinorita, & Aryandono, 2021). More recently, obesity has even been identified as a leading risk factor for hospitalization and poor clinical outcome of SARS-CoV2 patients during COVID-19 pandemic (Mohammad et al., 2021).

Several dietary strategies have been suggested to tackle these issues, affecting carbohydrate and lipid metabolism. The most straightforward solution could be to reduce the carbohydrate portions or their absorption introducing dietary fibers (Bell & Sears, 2003). However, most people distaste such dietary modifications and report gastrointestinal issues (Udani, Tan, & Molina, 2018). Similar results can be obtained by inserting in the diet starches that resist digestion in the small intestine, thus acting like dietary fibers (Barrett & Udani, 2011). These starches are naturally found in several seeds, legumes and unprocessed whole grains, with a low glycemic index (GI).

A different approach could involve the use of some phytochemicals to slow down carbohydrate absorption. This could be achieved by preventing their intestinal hydrolysis, inhibiting the necessary enzymatic activity, namely amylase and glucosidase (Fukagawa, Anderson, Hageman, Young, & Minaker, 1990; Kaur et al., 2021).

α-Amylase (α-1,4-glucan-4-glucanohydrolases, E.C. 3.2.1.1) is a glycoprotein catalyzing the endohydrolysis of (1→4)-α-D-glycosidic linkages in polysaccharides containing three or more (1→4)-α-linked α-glucose units (Kandra, 2003). During the reactions catalyzed by mammalian and bacteria α-amylases, as shown in Figure 1, the formation of covalent β-linked carbohydrate–enzyme intermediates in which are involved two aspartate residues and one residue of glutamate occurs (Hasegawa, Kubota, & Matsuura, 1999; Yoon, Bruce Fulton, & Robyt, 2007).

The human isoform is a single peptide chain of 512 amino acids (about 57 kDa), requiring calcium ions for structural integrity (Saboury & Karbassi, 2000; Whitcomb & Lowe, 2007). This is one of the major secretory enzymes of the salivary glands and pancreas, playing a central role in the digestion of starch and the absorption of deriving simple sugars. The cleavage of α-β-(1→4) glycosidic bonds releases shorter oligosaccharides retaining the α-anomeric configuration, called dextrins (a mixture of maltose, maltotriose, and branched oligosaccharides of 6–8 glucose units with both α-1,4 and α-1,6 linkages). Other intestinal brush border enzymes (namely α-glucosidase, maltase, and isomaltase) in turn further hydrolyze dextrins, and the resulting sugars can then be absorbed. No terminal glucose or α-β-(1→6) glycosidic bonds are affected by amylase activity (de Sales, de Souza, Simeoni, de Magalhães, & Silveira, 2012). Structurally, all α-amylases are usually folded into three domains: A, B, and C. Domain A consists of a β/αα3-barrel, which is the core structure of the enzyme. Domain B is a sheet of four anti-parallel β-strands with a pair of anti-parallel β-strands. The binding site for calcium ion is located in this domain. Domain C consists of eight β-strands forming a Greek key motif.

Thus, α-amylase represents the crucial step in the initiation of the process of digestion and absorption of dietary polysaccharides (Tangphatsornruang, Naconsie, Thammarongtham, & Narangajavana, 2005). Therefore it can be the target for specific enzyme inhibitors,
allowing to reduce the rate of carbohydrate absorption, the real energetic intake after a meal, and the subsequent glycemic peak (de Sales et al., 2012; Li et al., 2021).

Several alternatives have been proposed: acarbose (commercially known as Prandase®, Glucobay®, Precose®) is the best known α-amylase inhibitor (α-AI). This is a low-MW synthetic tetrasaccharide analog (Figure 2) used as a prescription drug to tackle hyperglycemia in the treatment of type 2 diabetes mellitus (Barrett & Udani, 2011). Miglitol and voglibose are other drugs belonging to the same class. As shown by several clinical studies, acarbose effectively improves insulin sensitivity in subjects with impaired glucose tolerance or type-2 diabetes, reducing cardiovascular risks in subjects with metabolic syndrome (a cluster of risk factors including high triglycerides, low high-density lipoprotein cholesterol, and hypertension) (Barrett & Udani, 2011; Yamagishi, Matsui, Ueda, Fukami, & Okuda, 2009).

Several α-AIs are also naturally present in plants, where they act as defense chemicals from biotic stress (Barrett & Udani, 2011; Sun, Warren, & Gidley, 2019). Over 800 plant species have been reported to have antidiabetic activity (de Sales et al., 2012). In particular, alkaloids, polysaccharides, steroids, glycopeptides, terpenoids, and several polyphenols (including hydroxycinnamic acids, chalcones, epicatechin, flavans, and anthocyanins, as shown in Figure 2, have been described as possible low-MW drug candidates (Kaeswurm, Claasen, Fischer, & Buchweitz, 2019; Kaur et al., 2021; Li, Bai, Jin, & Svensson, 2022; Papoutsis et al., 2021).

Among natural inhibitors, however, much attention has been paid to certain proteins which interact with α-amylase, thus providing a protein–protein interaction capable of reducing hydrolyzing activity. Proteinaceous α-AIs can derive from microbial and plants sources (Li, Fan, & Zhao, 2022). The latter can be further divided into six different classes: the knottin-like type, the Kunitz type, the thaumatin-like type, the γ-thionin-like type, the cereal type, and the lectin-like type (recently well reviewed in Li et al., 2021). The first three classes only affect the amylases insects, and can be therefore used in agriculture as biological pest control methods.

However, some classes can interact with mammalian (and human) enzymes and thus represent a potential drug candidate for antidiabetic and overweight treatments. The greatest interest has been addressed toward legume lectin-like glycoproteins extracted from several legumes (Bharadwaj, Raju, & Chandrashekharaiah, 2018; Yamada, Hattori, & Ishimoto, 2001). In particular, the commercial proprietary PHASE 2® is produced from the common bean Phaseolus vulgaris, as well as other similar “carb controller” products (Barrett & Udani, 2011; Ramírez-jiménez, Reynoso-camacho, Tejero, León-Galván, & Loarca-Piña, 2015; Udani et al., 2018).

In this work, we review the recent Literature about their structure, mechanism of action and clinical efficacy, especially focusing in the last 10 years papers and clinical meta-analysis.
Among the described α-AIs, the proteinaceous ones from *P. vulgaris* L. (α-AIs) show a particularly high potential (Bosi et al., 2019). In fact, the common bean is a well-widespread cultivation worldwide, with several positive nutritional features. Besides, these inhibitors are generally recognized as safe (no side effects found, as for other plant inhibitors; Kusaba-Nakayama et al., 2000).

α-Amylase inhibitors are lectins (carbohydrate-binding proteins, causing agglutination or precipitation of cells, glycococonjugates, including glycoproteins). *P. vulgaris* expresses three main classes of lectins: α-AIs, phytohemaggulitins (PHA), and arcelins (ARL), as protection agents of seeds from biotic (i.e., insect predation) and abiotic stress (i.e., drought, salinity, and wounding) (Mojica & de Mejia, 2015; Moreno, Altabella & Chrispeels, 1990), all deriving from a single ancestral gene (Kluh et al., 2005). PHA is a mitogen, affecting the intestinal mucosa of mammals, whereas ARL prevent absorption of nutrients in insect larvae (Santimone et al., 2004). These components are regarded as antinutritional factors (Obiro, Zhang, & Jiang, 2008), but thermal denaturation (typically reached during cooking) inactivates anti-nutrient agents, adding nutritional value due to their high sulfur aminoacid content (Mojica & de Mejia, 2015).

Three main α-AIs can be found in common beans: isoform 1 (α-AI1), isoform 2 (α-AI2), and α-amylase inhibitor-like (α-AIL) (Ishimoto, Suzuki, Iwanaga, Kikuchi, & Kitamura, 1995; Obiro et al., 2008). All these proteins are specifically able to inhibit animal α-amylases, not affecting plant amylases (Moreno, Altabella, & Chrispeels, 1990). Due to their activity against insect amylases, these proteins have been proposed as insecticides against bruchid pests (Le Berre-Anton, Nahoum, Payan, & Rougé, 2000). In fact, their genes have been also transgenically expressed in other plants (such as tobacco and peas) to confer resistance to various insect pests (Altabella & Chrispeels, 1990; Schroeder et al., 1995).

On the other hand, only α-AI1 has a specific effect on mammalian (and thus human) amylases, being therefore the target for nutraceuticals clinical studies. Heterologous expression of α-AI1 in yeasts has also been recently described to improve potential large-scale production (Brain-Isasi, Álvarez-Lueje, & Higgins, 2017).

### 2.1 Amylase inhibitors genes

As aforementioned, seven types of natural protein inhibitors of α-amylases (α-AIs) have been identified, and six of these, namely the knottin-like type (Bhide et al., 2017), the γ-thionin-like type (Mojica, de Mejia, Granados-Silvestre, & Menjivar, 2017), the cereal type, the Kunitz type, the thaumatin-like type, and the lectin-like type (Richardson, 1991), are extracted from plants. The other type has been isolated from bacteria (Sumitani, Tsujimoto, Kawaguchi, & Arai, 2000). The molecular weights of these inhibitors range from 3 to 23 kDa (Bhide et al., 2017). The knottin-like type, the Kunitz-type, and the thaumatin-like type are able to inhibit amylase only in insects (Pereira et al., 1999).

The α-AI lectin-like glycoproteins have been isolated from legumes. They were named for their high degree of amino acid sequence homology compared with the lectin proteins abundantly expressed in these plants. The currently known α-AI isoforms present in the different cultivars of the legume, *P. vulgaris* are α-AI1 (Berre-Anton, Bompad-gilles, & Rouge, 1997; Hoffman & Donaldson, 1985), α-AI2 (Suzuki, Ishimoto, & Kitamura, 1994), α-AI3 (Finardi-Filho, Mirkov, & Chrispeels, 1996), α-AI4, and α-AI5 (Lee, Gepts, & Whitaker, 2002). All the α-AI isoforms are encoded by genes that are part of a gene cluster, which includes dlec1 (encoding lectin phytohemagglutinin PHA-E), dlec2 (encoding leukophytoagglutinin PHA-L), and Arc (encoding arcelin) (Mirkov et al., 1994; Novadi, Tsai, Gilbertson, & Gepts, 1993).

According to evolutionary studies, the gene cluster may have originated following gene duplication events (Novadi et al., 1993). The gene cluster encodes proteins that share similar characteristics in their secondary and tertiary structures, as they are basically made up of antiparallel β-sheets. ARL differ from PHA-E and PHA-L through the absence of a short amino acid sequence (gap deletion G3), which, if present, forms a short loop. α-AI1 and α-AI2 differ from ARL through the absence of two sequences (gaps deletions G1 and G2), which, if present, form two other loops.

Ultimately, the proteins α-AI1 and α-AI2 have the shortest sequences due to the deletion gaps G1, G2, and G3. The α-AIL protein (α-amylase inhibitor-like protein previously called α-AI3) differs from α-AI1 and α-AI2 mainly due to the insertion of 15 amino acids around position 115 (G2) of the primary structure (Finardi-Filho et al., 1996).

The α-AIs in the bean, similar to the other proteins encoded by the gene cluster, are synthesized in the endoplasmic reticulum (ER) as inactive preproteins to become active proteins once transported to the vacuoles. The transition from inactive to active protein involves several post-translational modifications by which the precursor is N-glycosylated and cut (except in the case of the α-AI1 isoform) at a conserved Asn residue to give rise to two subunits (called α and β) that assemble non-covalently (Figure 3) (Berre-Anton et al., 1997; Campbell et al., 2011; Moreno et al., 1990; Pueyo, Hunt, & Chrispeels, 1993; Yamaguchi, 1991).

The α-AIs of *P. vulgaris* generally show only small differences in their primary structures and in their N-glycosylation sites. αAI-1 was the first isoform of *P. vulgaris* to be isolated in 1945 (Bowman, 1945), molecularly characterized (Hoffman, Ma, & Barker, 1982; Moreno et al., 1990) and crystallized (Bompad-Gilles, Rousseau, Rougé, & Payan, 1996). In the ER, the preproteins undergo cleavage of the signal peptide and N-glycosylated sites on residues of Asn12, Asn66, and Asn140 (the numbers refer to the positions of the residues in the mature protein). Through the secretory pathway, the protein is transported to the vacuoles, where it undergoes a second proteolytic cut. Specifically, vacuolar proteases cut at the conserved Asn77 residue (the number indicates the position of the residue after removal of the signal peptide) and also at the Asn223 to remove the C-terminal portion, which is then used to direct the peptide transport to the
vacuoles. These post-translational modifications give rise to the α and β subunits, with molecular weights of 7,800 Da (77 amino acid residues) and 14,600 Da (146 amino acid residues), respectively (Moreno & Chrispeels, 1989; Yamaguchi, 1991). As shown in Figure 4, in the native protein, the protein subunits are then organized in a tetrameric structure $\alpha_2\beta_2$ (Lee et al., 2002; Mirkov et al., 1994).

Site-specific mutagenesis experiments have demonstrated the importance of the amino acid residue in position 77 of the mature protein for the acquisition of the native structure. In fact, the removal of the proteolytic cleavage site at Asn77 by substitution of the ATT codon with a GAT codon (Asn77 $\rightarrow$ Asp77) in the gene $\alpha$-AI1 encoding the $\alpha$-AI1 isoform leads to the expression of an inactive inhibitor (Pueyo et al., 1993). In the $\alpha$-AI-2 isoform, the proteolytic cleavage that gives rise to the $\alpha$ and $\beta$ chains occurs at Asn75. This isoform has an $\alpha$ subunit that is shorter, by two amino acids, than the $\alpha$ subunit of $\alpha$-AI1 (Ser56 and Tyr57 are missing). It is interesting to note that $\alpha$-AIL, while retaining Asn77 in its primary structure, does not undergo proteolytic cleavage, so it is a monomeric protein (Finardi-Filho et al., 1996).

By exploiting the ability of the protein isoform, $\alpha$-AI1, to interact with mammalian $\alpha$-amylases, Bompard-Gilles and coworkers crystallized the $\alpha$-AI1–PPA complex (porcine pancreatic $\alpha$-amylase-$\alpha$-AI1) in
Three-dimensional model structure of the PPA/-AI complex leads to conformational modifications of α-present (Asp197, Glu233, and Asp300, as shown in Figure am amino acid residues directly involved in acid Tyr190 residues of L2 into the active site of the enzyme, where three projecting the Tyr37 and Asp38 residues of L1 and the Tyr186 and residues 29 β-antiparallel sheet. In the inhibition process promoted by α, two hairpin loops in the inhibitor (L1 and L2) play an important role. The amino acid residues in the loop make direct and indirect hydrogen bonds via H2O molecules with the enzyme (see below). L1 includes residues 29–46, and L2 includes residues 171–190. The inhibitor–enzyme interactions lead to conformational modifications of α-A1 projecting the Tyr37 and Asp38 residues of L1 and the Tyr186 and Tyr190 residues of L2 into the active site of the enzyme, where three amino acid residues directly involved in acid–base catalysis events are present (Asp197, Glu233, and Asp300, as shown in Figure 5). Tyr37 of the inhibitor, as a result of conformational changes induced by interactions with the enzyme, forms hydrogen bonds with the Glu233 residue and part of the Asp300 residue present in the active site of the enzyme. The latter is also engaged in binding with a chloride ion. The flanking Asp38 residue of the inhibitor assumes a position favorable for the formation of a hydrogen bond with His201, which is also present in the active site of the enzyme. The formation of this hydrogen bond facilitates the interaction of Tyr186 with the enzyme, which is projected into the heart of the catalytic site, forming hydrogen bonds with the catalytic nucleophile, Asp197 (McCarter & Withers, 1996). The orientation of the L2 loop allows the formation of a hydrogen bond with the Asp197 residue of the enzyme, which will not be able to participate in the catalytic event as a nucleophile (McCarter & Withers, 1996). Asp300 in the enzyme, the third residue of the catalytic triad involved in the acid–base catalysis with the substrate, is blocked, as it forms two hydrogen bonds with the inhibitor: the first bond is established between the carboxyl of its side chain and the hydroxyl group of Ser189 in the inhibitor, and the second bond is established between its carbonyl oxygen and Tyr190 in the inhibitor.

Additional molecular information on P. vulgaris α-AIs was obtained after the isolation of the genes encoding the protein isoforms α-A2 and α-AIL (Finardi-Filho et al., 1996; Mirkov et al., 1994; Suzuki et al., 1994). The reconstruction of the primary structure of the two proteins allowed to define their hypothetical three-dimensional structures using the crystal structure obtained by Bompard-Gilles et al. (1996) for the PPA–α-A1 complex as a model. Despite the high degree of similarity of the three isoforms, α-A1, α-A2, and α-AIL, their specificities to different α-amylase enzymes vary. While α-A1 inhibits the activity of pig α-amylases and those of the insects Tenebrio molitor, Callosobruchus maculatus and Callosobruchus chinensis, the other two isoforms do not act on these enzymes. α-A2 inhibits the α-amylase of the Zabrotetes subfasciatus beetle (ZSA), while α-A1 does not. To explain whether these differences could be justified at the molecular level, the two isoforms, α-A2 and α-AIL, were modeled in three dimensions using PPA/α-A1 and PHA-L crystals as models (Hamelryck et al., 1996). Although all the isoforms had very similar three-dimensional structures, both α-A2 and α-AIL differed from α-A1 by some more or less extensive structural changes. The results of the crystallographic studies obtained by
Bompard-Gilles et al. (1996) confirmed, in detail, the hypotheses on the structural differences between α-AI, α-AI2, and α-AI5 formulated by Finardi-Filho et al. (1996). Similar to α-AI, the α-AI2 isoform is a glycoprotein consisting of two chains resulting from the proteolytic processing of a preprotein on an asparagine residue (Asn75) equivalent to the Asn77 of α-AI. The proteolytic cleavage of Asn75 occurs due to the deletion of two amino acid residues at the N-terminus of the α chain (Tyr34 and Asn35). Other molecular differences include the replacement of the Tyr37, Tyr186, and Tyr190 residues present in the α-AI with Val35, His175, and Phe179 in α-AI2. The α-AI2/PPA docking experiments revealed a binding pattern between α-AI2 and PPA similar to that found for the α-AI1–PPA complex. However, the deletion of the two amino acids and the amino acid substitutions in α-AI2 result in much weaker α-AI2–PPA interactions than those described for the α-AI1–PPA complex. In the α-AI2–PPA complex, 8 hydrogen bonds are established compared to the 15 hydrogen bonds in the α-AI1–PPA complex. These weak interactions justify the inability of α-AI2 to inhibit PPA. Although their overall three-dimensional structures are very similar, α-AI2 differs from α-AI or α-AI2 as a result of two extra loops of 15 (stretch 95–109) and 6 (stretch 121–126) residues that are absent in α-AI1 and α-AI2. Furthermore, α-AI2, unlike the two other inhibitors, does not undergo any proteolytic cleavage, as shown in Figure 3: it is a single-chain protein. The docking experiments performed with PPA show that, based on these structural differences, α-AI2 cannot bind to the catalytic site of enzymes PPA and ZSA.

The docking experiments conducted using the α-AI2 isoform and the ZSA enzyme have highlighted the establishment of 12 hydrogen bonds compared with only 8 hydrogen bonds that are formed in the α-AI1–ZSA complex. Since ZSA is inhibited only by α-AI2 (Grossi de Sa et al., 1997), the network of 12 hydrogen bonds that is established between ZSA and α-AI2 is sufficient to stabilize the complex. Conversely, the network of eight hydrogen bonds observed between α-AI1 and ZSA would not be strong enough to stabilize this complex, and this may explain why α-AI1 does not inhibit ZSA.

The information obtained during the molecular studies conducted on the α-AI isoforms was exploited with the aim of highlighting additional coding genes and therefore other protein isoforms of the inhibitor. Chriseeples and Raikhel (1991) reported that these genes encode proteins highly conserved in the amino (presence of MASSK/N residues) and carboxyl terminals (LNQ/KIL residues), suggesting the importance of the sequences for synthesis in the ER and transport to the vacuole. Using pairs of primers on the nucleotide regions with maximum amino and carboxyl terminal homology, researchers performed PCR experiments to analyze DNA extracted from cultivar WKB 858 and black bean (BB) cultivar of P. vulgaris (Lee et al., 2002). The sequencing of the PCR products allowed the identification of two genes (α-AI4 for the 858 cultivar and α-AI5 for the BB cultivar) highly homologous to the other genes coding for the α-AIs. The primary structures of the two isoforms deduced from the nucleotide sequences of α-AI4 and α-AI5 were compared with those of the isoforms α-AI1, α-AI2, α-AI5 (homology 93–77%), and with those of PHA-E, PHA-L, and ARL proteins (homology 55–40%). The high-sequence homology strongly confirmed that these genes evolved from a common ancestral gene (Lee et al., 2002). The primary structures of the two isoforms, α-AI4 and α-AI5, were similar to those of the other isoforms. They all had three N-glycosylation sites and the recognition sequence for the peptidease that cuts the link between Ser21 and Ala22. The two isoforms also had the recognition sequence for the vacuolar protease that cuts the bond between Asn77 and Ser78, in line with what has been reported for the α-AI1 and α-AI2 isoforms.

The interaction between α-AI1 and amylases seems to happen in the same site of acarbose (Payan, 2004; Qian, Haser, Buisson, Duee, & Payan, 1994).

The three-dimensional structures of these two isoforms, based on the information obtained from the crystallographic studies of the α-AI1–PPA complex, highlight the presence of the three residues (Arg74, Trp188, Tyr190) important for the inhibition of α-amylase. In particular, it has been suggested that the active inhibitor site consists of Trp188 (β subunit), Arg74 (α subunit), and Tyr190 (β subunit), resembling the Trp-Arg-Tyr motif of bacterial α-AI tendamistat (Mirkov et al., 1995). In this perspective, the proteolytic activation at Asn77 may be necessary to bring these residues in close proximity. Besides, two tyrosines (Tyr37 and Tyr186) from the two hairpin α-A1 loops interact with two key residues in the enzyme active Asp197 and Glu233 (Payan, 2004). These two nucleophilic and acid functions act as crucial catalysts in the amylase action.

Besides, further protein–protein interactions involve areas away from the active site, including the loop 303–312, the loop at position 237–240, the loop 347–357, and the loop 140–150 from domain B (Payan, 2004). However, some differences in α-A11 inhibition have been observed between human and pig pancreatic amylases, being possibly due to the aminoisocyclic sequence dissimilarity in the two enzymes (Nahoum et al., 2000). For instance, some additional hydrogen bonds between inhibitor and human enzyme domain B have been observed, as well as different patterns of interactions in the loop regions 303–312 and 347–357 of domain A (Payan, 2004).

On the whole, this complex network of protein–protein interactions mimics the substrate binding in several subunits of the enzyme structure, inducing a steric hindrance process blocking the access of starch to the active site, which prevents hydrolysis. However, this process seems to be different if compared with the action of carbohydrate inhibitor acarbose. In this case, conformational changes have been reported in the flexible loop (residues 303–309), in the loop 237–240, and in the segment at position 140–150 of the domain B (Payan, 2004; Qian et al., 1994). The main residues involved are the catalytic residue Asp300 and residue His305, which undergo deep conformational changes. After substrate binding, the flexible loop moves toward the inhibitor, leading to a reduction of the cleft breadth. On the contrary, when α-A11 binds the enzyme, a tight-binding process occurs, pushing away the same loop toward the solvent. The loop region 351–359 in domain A undergoes significant structural modifications, while Asp 300 does not modify the orientation if compared with free amylase.
However, the process of α-AI1 has not been completely elucidated, being the role of some residues still not completely and universally understood (Obiro et al., 2008). This should encourage further studies, in perspective of the development of more (semi)synthetic inhibitors (see below).

All the α-AI isoforms, despite having a high-sequence homology overall, differ consistently in their upstream and downstream regions, which contain the amino acid residues responsible for the formation of hydrogen bonds with the active site of α-amylases (Lee et al., 2002). It is probable that the low-sequence homology in this region is responsible for each isoform’s specificity for α-amylases. In fact, studies on the α-AI1 and α-AI2 isoforms have shown that the differences in these regions lead to a different orientation of the L1 and L2 hairpin loops when the inhibitor comes into contact with the active site of the enzyme. Knowing the structural details of this family of plant α-AIs and their mechanism of action could help to understand their important roles in the control of endogenous amylases and in the protection against pathogens and parasites. Such pieces of information could also enhance the development of new inhibitors resembling the mechanism of α-AIs.

2.2 Structural properties

In the common bean, α-AI is a 43 kDa-residue polypeptide with three disulfide bridges that includes different isoforms (see above) (Berre-Anton et al., 1997; Pallaghy, Norton, Nielsen, & Craik, 1994). As stated above, the active sites of amylases usually comprise three key amino acids, namely Asp197, Glu233, and Asp300 (Brayer, Luo, & Withers, 1995). The α-amylase-binding site could hold at least six monosaccharide structures and be cleaved between the third and fourth pyranose residues by a double displacement mechanism (Pereira et al., 1999).

The inhibitor α-AI1 is purified from a variety of kidney bean seeds and is a 43 kDa tetrameric glycoprotein (α2β2) with a Stokes radius of 29.0 Å, which corresponds to globular proteins. Chemical and enzymatic deglycosylation methods gave M, calculated from sodium dodecyl sulfate–polyacrylamide gel electrophoresis (PAGE) experiments of about 7.8 and 14 kDa for α and β subunits, respectively (Yamaguchi, 1991). All these protein fractions react with biotinylated ConA, thus indicating they are glycosylated. The branched glycans linked to Asn65 and Asn140 of α-AI1 residues, protrude in the solvent at the back face of the dimer (Santimone et al., 2004).

α-AI1 has in turn two isoforms in P. vulgaris cv Tendergreen, α-AI1 and α-AI1’, which differ from each other by their isolectric points and neutral sugar contents (Berre-Anton et al., 1997; Kasahara et al., 1996). Both α-AI1 and α-AI1’ give a single protein band when analyzed by PAGE in native conditions, with an estimated M, of 43.6 and 39.8 kDa, respectively (Berre-Anton et al., 1997). The yield of neutral sugar contents of α-AI1 and α-AI1’ is 16% and 14% (w/w) respectively as estimated according to the phenol–H2SO4 method (Dubois, Gilles, Hamilton, Rebers, & Smith, 1956). According to the vapor phase chromatography, the oligosaccharide chains of both inhibitors are mainly composed of mannose associated to a trace of xylose (Yamaguchi, Funaoaka, & Iwamoto, 1992). α-AI1 is a lectin-like amylase non-competitive inhibitor that has been found both in mammalian and two kinds of insects’ amylases that come from C. maculatus and C. chinensis (Li et al., 2021).

The occurrence of two extra-loops on the front face of α-AIs prevents these proteins from entering the substrate cleft of PPA; thus, the removal of these loops appears as a structural requirement for the α-amylase inhibitory activity of α-AIs. In addition, as discussed above (Figure 4), the proteolytic processing occurring at Asn77 residue, which cleaves the polypeptide chain of α-AI1 in an α-chain (residues 1–77) and in a β-chain (residues 78–223), is necessary to transform an inactive precursor in a fully active inhibitor (Pueyo et al., 1993).

Several studies confirmed that α-AI1 interacts with a large region that surrounds the substrate-binding site of PPA in a slow process and forms a 1:2 stoichiometric complex which exhibited an optimum pH of 4.5 at 30°C (Berre-Anton et al., 1997; Franco, Rigden, Melo, & Grossi-de-Sá, 2002). The total buried area contributed by both molecules in this complex is about 3,050 Å², which is reported to be one of the largest values for a protein–protein complex (Bompard-Gilles et al., 1996). α-AI1 was also similarly shown to interact with the T. molitor α-amylase (Virginie Nahoum et al., 1999).

2.3 Operational stability

Several factors affect α-AI activity, including pH, temperature, and several ions. While mammalian amylase presents the highest activity close to neutrality (6.5–7), the optimum of pH for inhibitory activity has been identified in a slightly acidic environment, in the range 4.5–5.5 (Kotaru et al., 1987; Lajolo & Filho, 1985; Marshall & Lauda, 1975; Powers & Whitaker, 1978), being almost inactive outside this range (Berre-Anton et al., 1997). Lajolo and Finhardi Filho highlighted a specific difference between salivary (4.5) and pancreatic amylases (5.5) (Lajolo & Filho, 1985). Other authors showed an optimum at neutrality using porcine pancreatic amylase, but no incubation was performed in this case (Gibbs & Alli, 1998). Similar values of pH (5.25) have been also shown to positively affect inhibitor purification (Wang, Chen, Jeng, & Sung, 2011).

In fact, incubation time seems to greatly affect inhibitory activity, possibly explaining the different pH optima observed. A period of time comprised between 10’ and 120’ has been used to reach optimum activity (Berre-Anton et al., 1997; Marshall & Lauda, 1975; Powers & Whitaker, 1978): shorter incubation was in fact necessary when operating at pH 4.5. These findings suggest that, to obtain in vivo effects, nutraceutical preparations based on α-Al should be ingested before the meals, or at least at the same time (Obiro et al., 2008). The pre-incubation pH could also enhance α-Al effects. For instance, 20’ at pH 4 led to a boost of inhibition (Kluth et al., 2005), even though these data were collected on insect amylases.

Incubation times and pH seem to interfere also when the temperature effect on α-Al is evaluated. In fact, when operating at pH 4.5, a maximum of activity between 22 and 37°C was observed, with no
significant differences within this range (Berre-Anton et al., 1997). Lajolo and Filho (1985) showed only a slight increase in activity in the range 25–45°C, incubating inhibitor and enzymes at pH 5.4. On the contrary, a 10-fold increase in activity has been detected pre-incubating the inhibitor at amylose optimum pH (6.9) (Marshall & Lauda, 1975). These findings could be explained by the lower energy barrier at acidic pHs (Lajolo & Filho, 1985). All studies agree on the complete loss of activity boiling at 100°C and refrigerating at 0°C (Berre-Anton et al., 1997; Marshall & Lauda, 1975; Valencia, Bustillo, Ossa, & Chrispeels, 2000). In a study on transgenic peas, however, α-AI retained almost all the inhibitory effect when treated for 5° at 80°C (an almost complete drop in activity was observed for higher temperatures) (Collins, Eason, Dunshea, Higgins, & King, 2006).

Several ions also affect the binding between α-AI and amylase, and the consequent inhibitory effect. Particularly, calcium ion (5 mM) is important for the rate of initial binding (Gibbs & Alli, 1998). Chloride ion is also necessary to reach optimum activity (Gibbs & Alli, 1998; Lajolo & Filho, 1985). In fact, both these ions are usually present in the typical protocol commonly used for the determination of inhibitory activity. Potassium, magnesium, and sulfate ions did not interfere with α-AI biological activity (Gibbs & Alli, 1998), whereas a positive effect of nitrate, bromide, iodide, and thiocyanate ions has been described (Lajolo & Filho, 1985).

Taken together, all these data show several discrepancies about the optimal operational conditions for inhibition activity. This suggests the need of further studies to evaluate more carefully the interactions between pH, temperature, and incubation times, and to identify more precisely the best conditions for processing and administration of possible α-AI-based preparations.

### 3 | CLINICAL TRIALS

According to WHO, obesity is defined as abnormal or excessive fat accumulation. The body mass index (BMI), calculated by dividing a person’s weight in kilogram by the square of height in meters (kg/m²), represents a measure of obesity: a person is considered obese with a BMI ≥30.

The cause of excess body weight is an imbalance between energy intake and expenditure.

The WHO identifies two main factors which can cause the obesity condition: on one side the increasing intake of food rich in fat and sugar but lacking in vitamins and minerals, and on the other the decrease in physical activity due to an increase in sedentary works, urbanization, and motorized transports (WHO, 2021).

As mentioned above, many in vivo studies have shown that extracts of P. vulgaris have anti-obesity effects in animals and human models, presenting several advantages if compared to traditional dietary or pharmacological interventions (Bosi et al., 2019; Kusaba-Nakayama et al., 2000). On the contrary, in vitro models have not been usually employed. In fact, the overall effect on blood glucose of α-amylase:α-AI interaction can be difficulty observed by such models. So, in this review we focused only on in vivo studies.

#### 3.1 | In vivo studies on animal models

Many studies related to the administration of α-AI extracts to rats have been collected in a paper review by Carai et al. (2009). Unfortunately, the different ways used to express enzyme and/or inhibitor activities in units rather than in absolute weight terms make comparisons not easy to obtain.

The inhibition of the growth rate in rats fed with raw P. vulgaris beans and extract changes biochemical parameters and alteration in organ histology, as reported since the 1960s (Kakade & Evans, 1966; Maranesi, Barzanti, Biagi, Careneni, & Gentili, 1984; Maranesi, Carrenini, & Gentili, 1984). Only a transitory pancreatic enlargement was observed in young healthy rats consuming raw kidney beans chronically, accompanied by a significant reduction in body content of lipid and a lower body weight gain compared with control group (Grant, Dorward, Buchan, Armour, & Pusztai, 1995).

A weight loss (WL) was also observed after the administration of purified α-AI for 10 days, but it was accompanied by intestinal blockage (cæcum level) by solidified digesta in healthy Lister Hodded rats, since starch digestion was almost completely blocked (Pusztai et al., 1995). This effect, recorded only when the highest inhibitor concentrations (20 and 40 mg/kg) were administered, was linked to bacterial fermentation causing the hypertrophic growth of the tissue leading in some cases to the organ rupture.

On the contrary, using a different dry P. vulgaris extract, the administration of various doses (0, 50, 200, and 500 mg/kg) for 10 days did not imply side effects, but a reduction in rat body weight associated with a decrease in food intake was observed (Fantini et al., 2009).

This anorexigenic effect, observed by many authors (Loi et al., 2013; Shi et al., 2020; Torno, Gil-Exojo, de Tejada, & Campillo, 2004; Torno, Gil-Exojo, de Tejada, & Campillo, 2006), may be related to the lectin activity on the intestinal brush border, by altering the release of cholecystokinin and glucagon-like peptides that play an important role in the control of appetite. This phenomenon has been observed also when high palatable food was administrated to rats (Carai et al., 2009; Fantini et al., 2009).

It has been demonstrated that P. vulgaris extract is also effective in reducing glycemia in healthy and diabetic rats (Torno et al., 2004; Torno et al., 2006), as well as glucose absorption.

It is interesting that the antihyperglycemic activity is more effective if the P. vulgaris seeds are mixed with glibenclamide, an oral hypoglycemic agent. It was demonstrated that the combination of 300 g/kg (weight of seeds per body weight) with 0.20 g/kg body weight of glibenclamide results in a safer and potent hypoglycemic and antihyperglycemic activity in chronic diabetic conditions (Ocho-Anin Atchibiri, Brou, Kouakou, Kouadio, & Gnaki, 2010).

Different results were obtained when crude white bean flour was administrated (1 g/kg body weight) to diabetic-induced Wistar rats for 21 days; no significant decrease in blood glucose was recorded in this case (Pereira et al., 2012).

These different results could be linked to the different degree of purification of the extract in accordance with what observed in human...
model (see below) to various dosages and to the absence of a joint action with hypoglycemic agents.

Similarly, no significant WL, change in organ weight, food consumption, and blood biochemical parameters were recorded also in healthy Sprague–Dawley rats that received white kidney bean extract at doses 4, 2, and 1 g/kg for 90 days (Qin et al., 2019).

Qin et al. (2019) suggest that this difference could be related to the experimental group state of health. Healthy rats are in fact probably more resistant to α-AI effect compared with obese rats. Previous studies showed that amylase activity is higher in healthy subjects than in obese subjects (both rats and humans) (Kondo, Hayakawa, Shibata, Sato, & Toda, 1988; Schneeman, Inman, & Stern, 1983), and so the inhibitor could act more effectively on healthy individuals.

The studies on animal models (as summarized in Table 1) have shown the potential of *P. vulgaris* extract as anorexigenic and antihyperglycemic agent although these properties depend on the type of extract administered, the duration of the trial, and the health state of animals.

These results have laid the foundations for studying the role of beans extracts on human being with particular regard to the safety of the administered product.

### 3.2 Early studies on humans

The α-AI from *P. vulgaris* powder has also been tested on human models.

Many of the early studies carried on in 70s and 80s on the bean extract inhibitor are discussed in different reviews (Barrett & Udani, 2011; Obiro et al., 2008; Udani, Hardy, & Kavoussi, 2007).

In the first studies, crude white bean-based extracts were used. The results were disappointing; no decrease in human starch digestion was observed because of insufficient inhibitor activity and instability (Bo-Linn, Ana, Morawski, & Fordtran, 1982; Carlson, Li, Bass, & Olsen, 1983; Hollyenbeck et al., 1983).

A series of subsequent and more promising studies were published by a research group from the Mayo Clinic (Rochester, MN, USA) in the 1980s using a partially purified white bean product (Layer, Carlson, & DiMagno, 1985; Layer, Zinsmeister, & DiMagno, 1986).

In vitro it was found that the partially purified inhibitor inactivated intraduodenal, intraleral and salivary amylase without being affected by exposure to gastric juice (Layer et al., 1985).

These findings were also confirmed in vivo, by the reduction of amylase activity in the duodenal, jejunal, and ileal intralumens after the administration of partially purified amylase inhibitor accompanied by a significant reduction of gastric inhibitory polypeptide (GIP) concentration (Layer, Rizza, Zinsmeister, Carlson, & DiMagno, 1986).

These results were later confirmed by other authors who observed as the partially purified extract significantly reduced absorption of complex carbohydrates from the terminal ileum and decreased GIP concentration (Brugge & Rosenfeld, 1987; Jain et al., 1989).

In a series of studies, several doses of partially amylase inhibitor were administered to both healthy and diabetic subjects. A reduction in starch digestion and in postprandial glucose, C-peptide, insulin, and GIP level was recorded (Boivin, Flourie, Rizza, Go, & DiMagno, 1988; Boivin, Zinsmeister, Go, & DiMagno, 1987). The only side effect was represented by a temporary diarrhea, and the authors suggested that impurities in the partially purified preparation may be responsible for this side effect.

### Table 1 Main studies on animal models to test the efficacy of *Phaseolus vulgaris* extract

| Reference                        | Administration       | Subjects       | Side effects                          | Main results                                      |
|----------------------------------|----------------------|----------------|--------------------------------------|--------------------------------------------------|
| Grant et al. (1995)              | Raw beans            | Healthy rats   | Transitory pancreatic enlargement    | Reduction in body lipid level                     |
| Puszta et al. (1995)             | Partially purified   | Healthy rats   | Intestinal blockage (cecum level) by solidified digesta | Weight loss                                      |
| Fantini et al. (2009)            | Dry extract          | Healthy rats   | No side effects                       | Reduction in rat body weight, glycemia and a decrease in food intake |
| Tormo et al. (2006)              | Purified extract     | Healthy rats   | No side effects                       | Reduction in glycemia and decrease in food intake in both group |
| Loi et al. (2013)                | Partially purified   | Healthy rats   | Not available                         | Reduction in normal and palatable food intake ang glycemia |
| Tormo et al. (2004)              | Purified extract     | Healthy rats   | No side effects                       | Anorexigenic effect, reduction in weight gain, and blood glucose level |
| Ocho-Anin Atchibri et al. (2010) | *P. vulgaris* seeds + gilbenclamide | Diabetic rats | No side effects                       | Potent hypoglycemic and antihyperglycemic activity |
| Pereira et al. (2012)            | Bean flour crude     | Diabetic rats  | No side effects                       | No change in physiological parameters, in biochemical marker and organ weight |
| Qin et al. (2019)                | Aqueous extract      | Healthy rats   | No side effects                       | No significant weight loss, change in organ weight, food consumption, and blood biochemical parameters |
Similar results were obtained by Layer, Rizza, et al. (1986), testing 13 subjects (eight healthy volunteers and five subjects with type 2 diabetes). The effect of a partially purified bean-derived amylase inhibitor was recorded on the ingestion of 50 g of a test meal made of rice, cocoa, and aspartame. Also in this case, a decrease in postprandial plasma glucose and insulin concentration in both healthy and diabetics subjects was observed.

In 2000, the first study was conducted to investigate the effectiveness of white bean extract in WL (Thom, 2000).

An inhibitor product (Sucro-Bloc®) tablet (containing 200 mg of white kidney bean extract, 200 mg of inulin, and 50 mg of Garcinia cambogia extract) was administered to 40 overweight healthy subjects (BMI between 27.5 and 39).

In this randomized, double-blind, placebo-controlled trial the subjects had to eat two inhibitor tablets after all three meals per day for 12 weeks. After 3 months, a significative WL, a reduction of BMI, and a decrease of body fat percentage in the tested group were recorded. No side effects were recorded in the experiments.

These papers confirmed the preliminary results obtained in the animal models. Not only the inhibitory activity is unaffected by gastric juices, but it reduces the absorption of complex carbohydrates and lowers blood glucose concentration, C-peptide, and GIP levels, with almost negligible undesirable effects.

Moreover, the extract effectiveness in WL laid the groundwork for the study of commercial products that could be used as dietary supplements in the fight against obesity and diabetes. Further experiments became, in fact, necessary to improve purifications techniques and to test the safety of the product.

### 3.3 PHASE 2: Commercial products

Subsequent studies have focused on using the starch blocker IQP-PV-101, known commercially as PHASE 2, but previously named Phaseolamin 2250, because 1 g of the product blocked 2,250 starch calories (Preuss, 2007). It is also marketed globally under the Starchlite® and PhaseLite® brands (Grube, Chong, Chong, & Riede, 2014).

It is a dried aqueous extract from the common white bean P. vulgaris (Pharmachem Laboratories; Kearny, NJ, USA) produced from non-GMO whole kidney beans and certified as gluten free. It is used as a dietary supplement (odorless and tasteless) in various forms, including powders, tablets, and capsules.

Each lot of PHASE 2 has at least 3,000 α-amylase-inhibiting units (AAIU) per gram when tested at a pH 6.8 using potato starch as substrate and pancreatin as enzyme source (Barrett & Udani, 2011).

As declared in the Evaluation of the Generally Recognized as Safe (GRAS) status of PHASE 2 white bean (P. vulgaris) extract, a typically recommended dose is 1–2 capsule containing each 500 mg of PHASE 2, taken three times a day during daily meals, or 1,500–1,300 mg per day (Nicolosi, Hughes, & Bechtel, 2007). Heat treatments inactivates the hemagglutinating power and trypsin activity, thus ensuring the product safety (Chokshi, 2007).

### 3.4 Meta-analysis on clinical trials

Many clinical studies about PHASE 2 are collected in two meta-analyses. The most recent has been proposed by Udani et al. (2018), investigating the effectiveness of PHASE 2 in reducing body weight and fat.

They only included in their analyses those studies that met the main requirements collectively termed PICOS (Population, Intervention, Comparison, Outcomes and Study) criteria: Participants had to be obese or overweight; Intervention had to be done with PHASE 2; the Control group had to be compared with the test group; Outcome measurements had to include measurements of body or fat mass; and Study design had to be based on double-blind, placebo-controlled parallel or crossover trial, randomized or open-label studies.

Based on these characteristics, they selected 11 studies for meta-analysis for WL with a total of 573 subjects, and 3 studies for meta-analysis for fat loss with a total of 110 subjects.

They found that the intake of PHASE 2 resulted in a WL difference of 1.08 kg and in a fat reduction of 3.26 kg.

These conclusions partially contradict what was previously stated by Onakpoya, Aldaas, Terry, and Ernst (2011) in a previous meta-analysis: in fact they did not find any significant difference in WL between treated and control group.

As suggested by Udani et al. (2018), this difference may be due to the choice to include in the Onakpoya meta-analyses all studies on P. vulgaris, and not only on PHASE 2. These differences could have led to the inclusion of studies based on different partially purified preparations. However, also the meta-analysis from Onakpoya et al. showed a significant effect on fat loss, confirming a sharper effect on this body parameter.

### 3.5 Studies on WL in humans

Many authors focused their attention on testing the effectiveness of PHASE 2 in the loss of body weight and body composition (as summarized in Table 2).

In a series of papers, Udani and coworkers investigated the role of PHASE 2 in decreasing body weight, triglyceride (TG) level, and reducing waist size.

They did not achieve a significant statistical difference between active and placebo group in WL, by lowering TG level and reducing waist size, but they underlined the potential of PHASE 2 in the treatment of obesity and hypertriglyceridemia (Udani et al., 2004; Udani & Singh, 2007).

Different conclusions were reached by Celleno et al. (2007). Their results showed that the extract of P. vulgaris significantly contributes to reduction of body weight, BMI, fat mass, adipose tissue thickness, and waist, hip and thigh circumferences in overweight treated subjects. At the same time the lean body was preserved.

A similar study was carried out in 2010 on overweight men and women (Wu et al., 2010) in which a statistically significant difference was recorded in reduction of body weight and waist circumference in
an active group compared with a placebo group. On the other hand, no significant change in hip circumference was recorded. More recently PHASE 2 was tested for its efficacy in WL and weight maintenance (WM) in subjects with BMI between 25 and 35 kg/m² (Grube et al., 2014). This research is of particular importance for the sample size of the WL trial and for the duration of WM study (the largest sample, 123 subjects, and the longest single clinical trial, 24 weeks, respectively) conducted on *P. vulgaris* extract. It proves the efficacy of the product in WL after 12 weeks (2.91 ± 2.63 kg vs. 0.92 ± 2.00 kg, *p* < .001) and in WM after 24 weeks (the mean weight of the subjects at week 24 was 99.34 ± 2.96% of baseline weight).

The growing interest in this research field is emphasized by a very recent paper that studies WL in obese subjects after the intake of 2,400 mg of *P. vulgaris* extract before each daily meal in a short period (35 days) (Wang et al., 2020). The differences in WL between the active and placebo group were significant (*p* < .1; 2.24 kg vs. 0.29 kg). BMI decreased by an average of 0.79 kg/m² and the body fat decreased by 1.53% on average compared with the baseline. Other recorded parameters were thickness of subcutaneous fat, waist, and hip circumference that significantly decreased after the treatment.

These studies demonstrated the effectiveness of the commercial product PHASE 2 in the treatment of obesity. Weight loss, reduction in BMI, and decrease in waist circumference are the main effects of taking this food supplement.

However, other important issues have been investigated to evaluate the effect of *P. vulgaris* extract in reducing postprandial plasma glucose, hyperglycemia, and insulin response.

### 3.6 Effect of α-A1 on hyperglycemia and hyperinsulinemia in humans

One of the obesity-related diseases is diabetes mellitus, a metabolic disorder characterized by chronic hyperglycemia. Many therapies have been proposed by the scientific community to treat type 2 diabetes; the use of α-AIIs to lower postprandial plasma glucose and insulin concentration has already been studied since 1973 on rats and dogs (Boivin et al., 1987; Layer, Rizza, et al., 1986). As mentioned above, both Boivin et al. (1987) and Layer, Rizza, et al. (1986) showed that a partially purified amylase inhibitor was able to decrease postprandial plasma glucose and insulin concentrations in both healthy and diabetic subjects. More recently, a new commercial supplement produced with the intent of preventing obesity and diabetes was tested in Barrious Laboratories (Yamada et al., 2007). This granular supplement contains PHASE 2, *Coleus forskohlii* extract and mushroom chitosan.

| Reference | Duration | Subjects | Dose of PHASE 2<sup>®</sup> | Main results | Trial type |
|-----------|----------|----------|-----------------|--------------|-----------|
| Udani, Hardy, and Madsen (2004) | 8 weeks | *n*= 39 | 1,500 mg twice a day | No significant difference in WL and triglyceride level | Randomized, double-blind, placebo-controlled |
| Udani and Singh (2007) | 4 weeks | *n*= 25 | 1,000 mg twice a day | No significant difference between in WL and reducing waist size | Double-blind, placebo controlled |
| Celleno, Tolaini, D’Amore, Perricone, and Preuss (2007) | 4 weeks | *n*= 60 | 445 mg | Statistically significant difference in reducing BW, BMI, fat mass, adipose tissue thickness, and waist, hip, thigh circumferences. Lean body preserved | Randomized, double-blinded, placebo controlled |
| Wu, Xu, Shen, Perricone, and Preuss (2010) | 8 weeks | *n*= 101 | 2,000 mg | Statistically significant in reduction in BW and waist circumference. No significant change in hip circumference | Randomized, double-blinded, placebo controlled |
| Grube et al. (2014) | 12 weeks | *n*= 123 | 1,000 mg three times a day | Statistically significant difference in WL, waist circumference and BMI reduction | Randomized, double-blinded, placebo controlled |
| Grube et al. (2014) | 24 weeks | *n*= 49 | 1,000 mg three times a day | 73.5% of WM | Randomized, double-blinded, placebo controlled |
| Wang et al. (2020) | 35 days | *n*= 120 | 2,400 mg | Statistically significant difference in BW, BMI, fat mass, adipose tissue thickness, and waist circumferences | Randomized, double-blinded, placebo controlled |

Abbreviations: BMI, body mass index; BW, body weight; WL, weight loss; WM, weight maintenance.
In a double-blind crossover test including 13 men and women with a fasting blood-glucose level above 126 mg/L, the active product or the placebo (in a single dose) were administered 5 min before eating 300 g of polished rice. The analysis of blood glucose levels measured before and after eating (30–120 min later) showed that blood sugar levels and insulin levels were significantly lower in the active group as compared with the placebo group measured respectively 30 min and 30–60 after meal intake. Unfortunately, these results have not been published in a peer-reviewed journal.

On the other side, in 2009 three different independent papers focused on the same topic were published. In the first study differences in GI were investigated after the intake of white bread and butter with and without the addition of PHASE 2 (Udani et al., 2009). The GI is a scale that represents the rise of glucose level after food intake and is defined as “the incremental area under the blood glucose response curve of a 50 g carbohydrate portion of a test food expressed as a percent of the response to the same amount of carbohydrate from a standard food taken by the same subject”.

PHASE 2 was administered to 15 randomized volunteers with BMI between 18 and 25 (only 13 were considered in the final analysis) in a capsule or powder form at the dosage of 1,500, 2,000, and 3,000 mg. The GI was calculated using standard capillary glucose measurements.

The capsules with 2,000 and 3,000 mg of PHASE 2 reduced GI significantly, while the powder formulation was effective only with the highest dose administration.

The second study included two different placebo-controlled, cross-over tests (Vinson et al., 2009).

In the first trial, four slices of white bread and 42 g of margarine with or without 1,500 mg of PHASE 2 were administered to 11 normoglycemic subjects. With a clinical procedure, the blood was drawn before the meal and after every 15 min for 2 h. A faster return to the plasma glucose base line (62 vs. 80) was found in the active group compared with the placebo group and it was suggested that only 1/3 of the carbohydrates in the bread were absorbed with PHASE 2.

In the second trial, seven subjects consumed a frozen dinner of country fried steak with gravy, mashed potatoes, green beans, and cherry-apple pie with or without a lower PHASE 2 dose (750 mg). Blood was sampled every 10 min for 60 min then periodically until 2 h.

Also in this case, the active group returned to the baseline faster than untreated subjects (58 vs. 70 min) and only 2/3 of the carbohydrates was absorbed using PHASE 2.

In the third study, the hypoglycemic power of bean extract was also investigated in combination with acarbose on 12 healthy volunteers. The subjects were administered 1,500 mg P. vulgaris extract and 50 mg acarbose, or acarbose 50 mg alone, before a carbohydrate meal. However, no significant differences were found between the two groups in reducing postprandial glucose level (Zulkarnain et al., 2009).

In a more recent trial, the efficacy of P. vulgaris extract (Beanblock; Indena S.p.A., Milan, Italy) was investigated both on glycometabolic and appetite control (Spadafranca et al., 2013). In this double-blind, randomized, cross-over study, 20 healthy fasting volunteers were asked to eat a standardized meal consisting of a sandwich of white bread, ham, oil, and tomato with 100 mg of active or placebo tablet. The blood was drawn at baseline and periodically for 3 h after meal to record glucose, insulin, C-peptide, and ghrelin concentration.

The intake of the bean extract reduced the glucose response to the meal, accompanied by a lower insulin level and C-peptide excursions. The sense of satiety was significantly reduced in the placebo group compared with the active one (third hour after meal) as a result of the suppression of ghrelin secretion inducing a lower desire to eat in the active group.

Several studies have proved the efficacy of P. vulgaris extract in reducing postprandial blood glucose concentration and so it is

### TABLE 3 Main clinical trials on humans for the treatment of hyperglycemia and hyperinsulinemia with Phaseolus vulgaris extract

| Reference                        | Administration                      | Subjects                  | Side effects            | Main results                                                                 |
|----------------------------------|-------------------------------------|---------------------------|-------------------------|-----------------------------------------------------------------------------|
| Layer, Rizza, et al. (1986)      | Partially purified extract           | Healthy and diabetics     | Abdominal discomfort and diarrhea | Decrease in postprandial plasma glucose and insulin concentration in both subjects |
| Boivin et al. (1987)             | Partially purified extract           | Healthy                   | Diarrhea                | Reduction in starch digestion and postprandial glucose                     |
| Yamada, Yamamoto, and Yamaguchi (2007) | PHASE 2° + Coleus forskohlii extract + mushroom chitosan. | Diabetic                  | No side effects         | Reduction of GI after the administration of 2 and 3 g of PHASE 2°          |
| Udani, Singh, Barrett, and Preuss (2009) | PHASE 2 | Healthy                   | No side effects         | A faster return to the plasma glucose base line after a meal               |
| Vinson, Al Kharrat, and Shuta (2009) | PHASE 2 | Healthy                   | Not available           | Reduction in postprandial glucose concentrations                           |
| Zulkarnain, Setiawati, and Setiabudy (2009) | PHASE 2 + acarbose | Healthy | | |
suggested as a valuable tool to prevent the onset of diabetes (Mahmood, 2016).

PHASE 2 is effective in reducing blood glucose and insulin levels in both healthy and diabetic subjects confirming what has been observed in preliminary animal studies and early human trials. As noted above, the side effects of this supplement are mostly attributable to transient or even absent episodes of diarrhea.

However, more studies are necessary to explore this topic in more depth in order to resolve some discrepancies among the findings. This research field is in any case still open and the consumption of beans has even been proposed as a possible low-cost approach to reduce some ophthalmic disease such as cataract in patients with type 2 diabetes (Longo-Mbenza & Muaka, 2013).

4 | SAFETY

It should be noted that beans and their extracts also contain antinutritional compounds. Trypsin inhibitors, lectins such as phytohemagglutinin, polyphenols (condensed tannins and anthocyanins), and some oligosaccharides, in fact, counteract the beneficial effects deriving from their consumption (Los, Zielinski, Wojciechowski, Nogueira, & Demiate, 2018). The presence of these substances may interfere with digestibility and availability of nutrients (Worku & Sahu, 2017). Many studies have reported the occurrence of side effects and risk of adverse reactions after the ingestion of raw beans in humans and animals (Carmalt, Rosel, Burns, & Janzen, 2003; de Moya et al., 2003; Marzo, Alonso, Urdaneta, Arricibita, & Ibáñez, 2002).

Particular attention was given to PHA that, if administrated at high concentrations, causes hyperplastic growth of the small intestine, lower fractional rate of protein synthesis in skeletal muscle, and overgrowth of *Escherichia coli* in the lumen in a dose-dependent manner (Bardocz et al., 1992; Pusztai et al., 1993).

With the aim of removing the activity of antinutritional compounds, different techniques have been reported and summarized by Kumar, Verma, Das, Jain, and Dwivedi (2013) in a recent review. For example, it has been observed that PHA is inactivated by cooking (Nicir et al., 2015; Rodhouse, Haugh, Roberts, & Gilbert, 1990; Thompson, Rea, & Jenkins, 1983). Unfortunately, this treatment also inactivates α-AI.

Furthermore, since hemagglutination activity greatly differs among all cultivars (Burbano, Muzquiz, Ayet, Cuadrado, & Pedroso, 1999; Grant, More, McKenzie, Stewart, & Pusztai, 1983) and the α-AI is more active on some than others (Bosi et al., 2019; Ghorbani et al., 2018; Wang et al., 2011; Yao, Hu, Zhu, Gao, & Ren, 2016), it is crucial to choose a cultivar with less PHA concentration and more α-amylase activity as a raw material to produce bean extract.

However, the role of PHA in body WL is still debated. In fact, the intake of raw bean extract mixed in the diet with PHA lower than 0.2 g/kg leads to the reduction in body fat and body weight in obese Zucker rats (Pusztai et al., 1998). This group lost more fat compared with the control group without loss of skeletal muscle and body proteins.

A higher concentration (0.4 g/kg) of PHA was tolerated if accompanied by a higher lipid dose in the diet. Based on this evidence bean lectin has been suggested as a dietary adjunct to tackle obesity in a safe and effective dose range. However, when rats were fed with a high concentration of PHA and low in α-AIs, there was no hypoglycemic effect (Bardocz, Grant, Pusztai, Franklin, & Carvalho, 1996).

Therefore, the attention has turned to the preparation of *P. vulgaris* extract with a dual action: (i) inhibition of α-amylase and (ii) anorexigenic effect caused by PHA (Fantini et al., 2009).

PHASE 2 is instead prepared using a special process to inactivate hemagglutination power and trypsin inhibiting activity and many studies tested its safety. The finished product contains less than 700 hemagglutinating activity units (HA) per gram.

Acute and subacute toxicity on rats was investigated by several studies (Chokshi, 2006, 2007; Harikumar et al., 2005). No significant side effects or mortality was recorded in these trials. The toxicity level was considered acute when it exceeded the highest dose tested in acute administration corresponding to 5 g PHASE 2/kg BW (Obiro et al., 2008).

Moreover, the absence of side effects related to the presence of PHA confirmed the product safety. The effects of subchronic (30 days treatment) and chronic (24 weeks) use of PHASE 2 administration were studied on humans too, and no side effects were recorded (Celleno et al., 2007; Grube et al., 2014).

Despite most studies are focused on PHASE 2, it is not the only α-AI commercially available. In 2020 another carbo-blocker extracted from *P. vulgaris* called Max Bloc® was tested (Zhang, Cavender, & Allen, 2020). Compared with three other commercial carbo-blockers from China and the United States, it has a α-amylase inhibitory activity 10–16 times higher and no hemagglutinin toxicity (0 HAU/g vs. 256,000–640,000 HAU/g of the others).

Moreover in vitro studies have shown that the ingestion of Max Bloc reduces starchy food digestion by 69.2% to 93.3%. Based on this evidence, this supplement has been proposed as a valid candidate in weight management and glucose control.

On the whole, α-AI commercial products showed different characteristics probably linked to the different extraction procedures. These could also affect the real dose administered and the resulting effectiveness on the patient. The joint action of α-AI and PHA may improve the effectiveness of the product in a dose-dependent manner. Nevertheless, many of these studies look preliminary, thus more experiments should improve the safety and efficacy of these commercial products.

5 | THE MODULATION OF GUT MICROBIOTA

The increased awareness of the role of gut microbiota in human and animal health is leading to more investments and research on this topic (Conlon & Bird, 2015). It has been demonstrated that the diet plays a preponderant role in the modulation of microbiota, even more important than genetic factors (David et al., 2014).
It has been proved that the gut microbiota composition changes in lean and obese individuals thus revealing that obesity is associated with the reduction in the abundance of Bacteroidetes and with the increase in the abundance of Firmicutes (Turnbaugh et al., 2006).

Based on this evidence, some recent studies have focused their attention on the effects that *P. vulgaris* extracts may have on microbiota composition in mice (Shi et al., 2020; Song et al., 2016).

Shi et al. (2020) investigated the role of α-amylase extract in body weight, serum lipid levels, and gut microbiota composition in obese rats. During the experiment, three different doses of extract (0.5, 1, and 1.5%) were added to the diet and administered to induced obesity in rats for 10 weeks. At the end of experiments, rats fed with the two highest doses of extract showed a significantly lower BW. Under these conditions, abdominal fat accumulation, serum TC, and serum low density lipoprotein (LDL) levels were significantly reduced.

Interesting considerations have been made about the relationship among colonic content, pH, and the concentration of short-chain fatty acid (SCFA). Administration of medium and high dose of bean extract significantly increased the colonic content compared with obese and non-obese rats and led to a decrease in pH values of the colonic content (Shi et al., 2020).

This pH reduction is closely related to the increase of SCFA in intestinal content arising from the fermentation of carbohydrate by gut microbiota (Harris, Edwards, & Morrison, 2017; Poeikhampha & Bunchasak, 2010). The authors underlined the importance of SCFA in metabolic health, recalling that propionic acid (increased by medium and high doses) has an important role in the reduction of lipids level (Laparra & Sanz, 2010), thus suggesting that the lipid-lowering effects resulting from the administration of *P. vulgaris* extract may be related to this increase in propionic acid.

Important changes were also recorded in gut microbiota after the administration of different diets. The high-fat diet of the mice involved a reduction of diversity and richness in gut microbiota composition. However, the administration of *P. vulgaris* extract involved a reduction of the relative abundance of *Firmicutes* and *Proteobacteria*, and an increase of the relative abundance of *Bacteroidetes, Butyrivibrio, Blautia*, and *Eubacterium* (phylum level). The latter groups of bacteria are SCFA-producing, protecting the intestinal gut from damage preventing the onset of obesity and related diseases.

These conclusions are in agreement with what was found previously by Song et al. (2016) in the first study on the change in gut microbiota in diet-induced obese mice by administration of kidney beans extract. Similarly, rats have been divided into three groups (fed with low-fat diet, high-fat diet, and high-fat diet added with *P. vulgaris* extract) to monitor the body weight, serum lipid level, hepatic steatosis, and change in gut microbiota composition for 14 weeks.

Even in this case, the *P. vulgaris* extract treatment reduced body weight and food intake compared with animals fed with only high-fat diet. The high-fat diet involved an increase in TC (LDL, high density lipoprotein [HDL]), and serum triacylglycerols, while the administration of bean extract led to a reduction TG, TC, LDL but not HDL. The bean extract turned out to have an anti-hepatosteatosis effect and to cause a decrease in glucose blood levels in rats fed with a high-fat diet.

In accordance with the other study, the high-fat diet induced a significant increase of *Firmicutes* and decrease in *Bacteroidetes, Proteobacteria*, and *Verrucomicrobia*, while bean extract involved a decrease in the relative abundance of *Firmicutes*, but a significant increase in *Verrucomicrobia* and *Actinobacteria*. The increase of the relative abundance of *Bifidobacterium, Lactobacillus*, and *Akkermansia* was also recorded at the phylogenetic genus level.

So, it is evident that the subjects receiving the extract benefit both in terms of body WL, reduced blood glucose level, and intestinal health.

In addition, Wang et al. (2021) investigated the modulation of gut microbiota in high-fat fed C57BL/6J mice after 8 weeks of administration of *P. vulgaris* extract, yogurt, and a mixture of *P. vulgaris* extract and yogurt (YPVE) as additive feeding (Wang et al., 2021).

At phylum level, the Bacteroidetes and Proteobacteria in YPVE group was declined comparing with the other groups, while the abundance of *Firmicutes* in YPVE group remained higher than high-fat fed mice. The YPVE mice microbiota was characterized by richness and abundance of microbial species, suggesting that the YPVE led to a healthy direction on the regulation of intestinal flora.

In summary, the intake of *P. vulgaris* extract in mice has the potential to modulate gut microbiota. The microbiota of treated animals was characterized by a greater richness in species. It was recorded an increase of the relative abundances of *Bacteroidetes* and *Akkermansia* and a reduction of *Firmicutes* and *Proteobacteria*, with the proliferation of SCFA-producing bacteria, which reflects positively on the well-being of the host. These findings are in fact giving further impetus to research in this field. Many recent works are focused on the role of *P. vulgaris* intake in microbiota modulation in animal models (Dias et al., 2019; Gomes Mariana et al., 2021; Kilua et al., 2020). Human model should be the next step for further research, in order to confirm the health effects of *P. vulgaris* extract also at the intestinal level.

### 6 CONCLUSIONS AND FUTURE PERSPECTIVE

Many natural products are potentially useful for human health and can be extracted in sufficient quantities from natural sources. Among these substances, we can include the protein inhibitors of the mammalian α-amylase enzyme. Over the past 20–30 years, a large number of studies have been conducted that show the potential usefulness of these inhibitors, extracted from the seed of *P. vulgaris*, in producing strategies to contain the absorption of complex carbohydrates. The results of many clinical trials have generated encouraging results so as to induce the main American and European Control Authorities to issue authorizations to market common bean-based preparations.

Today, we can consider these preparations safe for human health although transient side effects can occur depending on the ingested doses. In this perspective, this review work could encourage further studies to better explore these issues, potentially affecting the real clinical efficacy of the commercial products (Izzo, Hoon-Kim, Radhakrishnan, & Williamson, 2016).
A further future perspective is to use genetic approaches to isolate \textit{P. vulgaris} lines devoid of active antinutritional lectin to product commercial snack, such as biscuits and crackers, maintaining \(\alpha\)-\textit{P. vulgaris} activity (Sparvoli et al., 2021).

Over 90% of the world’s bean production is done in developing countries. A challenge that awaits us in the coming years is to select among the thousands of cultivars of \textit{P. vulgaris} present in the world those with the most favorable inhibitor/anti-nutritional factor ratio, and whose cultivation can respond to criteria of greater sustainability for the environment.

**CONFLICT OF INTEREST**

The authors declare no conflicts of interest.

**DATA AVAILABILITY STATEMENT**

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

**ORCID**

Javad Sharifi-Rad \(\text{https://orcid.org/0000-0002-7301-8151}\)

Antonio Rescigno \(\text{https://orcid.org/0000-0002-2855-8378}\)

Paolo Zucco \(\text{https://orcid.org/0000-0002-3548-7635}\)

**REFERENCES**

Agarwal, P., & Gupta, R. (2016). Alpha-amylase inhibition can treat diabetes mellitus. Research & Reviews Journal of Medical & Health Sciences, 5(4), 1–8.

Altabello, T., & Chrispeels, M. J. (1990). Tobacco plants transformed with the bean alphaai gene express an inhibitor of insect alpha-amylase in their seeds. Plant Physiology, 93(2), 805–810. https://doi.org/10.1104/pp.93.2.805

Bardocz, S., Brown, D. S., Grant, G., Pusztai, A., Stewart, J. C., & Palmer, R. M. (1992). Effect of the beta-adrenoceptor agonist clenbuterol and phytohaemagglutinin on growth, protein synthesis and polyamine metabolism of tissues of the rat. British Journal of Pharmacology, 106(2), 476–482. https://doi.org/10.1111/j.1476-5381.1992.tb14359.x

Bardocz, S., Grant, G., Pusztai, A., Franklin, M. F., & Carvalho, A. D. F. U. (1996). The effect of phytohaemagglutinin at different dietary concentrations on the body composition and plasma insulin of the rat. British Journal of Nutrition, 76(4), 613–626. https://doi.org/10.1079/bjn19960067

Barrett, M. L., & Uddin, J. K. (2011). A proprietary alpha-amylase inhibitor from white bean (Phaseolus vulgaris): A review of clinical studies on weight loss and glycemic control. Nutrition Journal, 10(1), 1–10. https://doi.org/10.1186/1475-2891-10-24

Bell, S. J., & Sears, B. (2003). Low-glycemic-load diets: Impact on obesity and chronic diseases. Critical Reviews in Food Science and Nutrition, 43(4), 357–377. https://doi.org/10.1080/10408690390826554

Berre-Anton, L., Bombard-gilles, C., & Rouge, P. (1997). Characterization and functional properties of the alpha-amylase inhibitor (alpha-Al) from kidney bean (Phaseolus vulgaris) seeds. Biochimie et Biophysica Acta (BBA) – General Subjects, 1343, 31–40.

Bharadwaj, R. P., Raju, N. G., & Chandrashekhariah, K. S. (2018). Purification and characterization of alpha-amylase inhibitor from the seeds of underutilized legume, Mucuna pruriens. Journal of Food Biochemistry, 42(August), e12686. https://doi.org/10.1111/jfbc.12686

Bhide, A. J., Channale, S. M., Yadav, Y., Bhattacharjee, K., Pawar, P. K., Maheshwari, V. L., ... Girł, A. P. (2017). Genomic and functional characterization of coleopteran insect-specific \(\alpha\)-amylose inhibitor gene from \textit{Amaranthus} species. Plant Molecular Biology, 94(3), 319–332.

Boivin, M., Zinsmeister, A. R., Go, V. L., & DiMagno, E. P. (1987). Effect of a purified amylase inhibitor on carbohydrate metabolism after a mixed meal in healthy humans. Mayo Clinic Proceedings, 62(4), 249–255. https://doi.org/10.1016/0025-6196(87)91900-4

Boivin, M., Flourie, B., Rizza, R. A., Go, V. L. W., & DiMagno, E. P. (1988). Gastrointestinal and metabolic effects of amylase inhibition in diabetics. Gastroenterology, 94(2), 367–394. https://doi.org/10.1016/S0016-5085(88)90426-X

Bo-Linn, G. W., Ana, C. A. S., Morawski, S. G., & Fordtran, J. S. (1982). Starch blockers – Their effect on calorie absorption from a high-starch meal. New England Journal of Medicine, 307(23), 1413–1416. https://doi.org/10.1056/NEJM198212023072301

Bompard-Gilles, C., Rousseau, P., Rougé, P., & Payan, F. (1996). Substrate mimicry in the active center of a mammalian \(\alpha\)-amylose: Structural analysis of an enzyme-inhibitor complex. Structure, 4(12), 1441–1452.

Bosi, S., Bregola, V., Dinelli, G., Trebbi, G., Truzzi, F., & Marotti, I. (2019). The nutraceutical value of grain legumes: Characterisation of bioactive and antinutritional factors related to diabetes management. International Journal of Food Science and Technology, 54(10), 2863–2871. https://doi.org/10.1111/ijfs.14204

Bowman, D. E. (1945). Amylase inhibitor of navy beans. Science, 102(2649), 358–359.

Brain-Isaa, S., Álvarez-Lueje, A., & Higgins, T. J. V. (2017). Heterologous expression of an \(\alpha\)-amylose inhibitor from common bean (Phaseolus vulgaris) in Kloyveromyces lactis and Saccharomyces cerevisiae. Microbial Cell Factories, 16(1), 110. https://doi.org/10.1186/s12934-017-0719-4

Brayer, G. D., Luo, Y., & Withers, S. G. (1995). The structure of human pancreatic \(\alpha\)-amylose at 1.8 A resolution and comparisons with related enzymes. Protein Science, 4(9), 1730–1742. https://onlinelibrary.wiley.com/doi/10.1002/pro.5560040908

Brugge, W. R., & Rosenfield, M. S. (1987). Impairment of starch absorption by a potent amylase inhibitor. The American Journal of Gastroenterology, 82(8), 718–722.

Burbano, C., Muzzquiz, M., Ayet, G., Cuadradó, C., & Pedrosa, M. M. (1999). Evaluation of antinutritional factors of selected varieties of \textit{Phaseolus vulgaris}. Journal of the Science of Food and Agriculture, 79(11), 1468–1472. https://doi.org/10.1002/jsfa.109710000007

Campbell, P. M., Reiner, D., Moore, A. E., Lee, R.-Y., Epstein, M. M., & Higgins, T. J. V. (2011). Comparison of the \(\alpha\)-amylose Inhibitor-1 from common bean (Phaseolus vulgaris) varieties and transgenic expression in other legumes post-translational modifications and immunogenicity. Journal of Agricultural and Food Chemistry, 59(11), 6047–6054. https://pubs.acs.org/doi/abs/10.1021/jf200456j

Carai, M. A. M., Fantini, N., Loi, B., Colombo, G., Riva, A., & Morazzoni, P. (2009). Potential efficacy of preparations derived from \textit{Phaseolus vulgaris} in the control of appetite, energy intake, and carbohydrate metabolism. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2, 145–153. https://doi.org/10.2147/dmssott.s4236

Carlson, G. L., Li, B. U., Bass, P., & Olsen, W. A. (1983). A bean alpha-amylase inhibitor formulation (starch blocker) is ineffective in man. Science (New York, N.Y.), 219(4583), 393–395. https://doi.org/10.1126/science.6184780

Carmalt, J., Rosel, K., Burns, T., & Janzen, E. (2003). Suspected white kidney bean (\textit{Phaseolus vulgaris}) toxicity in horses and cattle. Australian Veterinary Journal, 81(11), 674–676. https://doi.org/10.1111/j.1751-0813.2003.tb12534.x

Celleno, L., Tolaini, M. V., D’Amore, A., Perricone, N. V., & Preuss, H. G. (2007). A dietary supplement containing standardized \textit{Phaseolus vulgaris} extract influences body composition of overweight men and women. International Journal of Medical Sciences, 4(1), 45–52. https://doi.org/10.7150/ijms.4.45
Chokshi, D. (2006). Toxicity studies of blockal, a dietary supplement containing phase 2 starch neutralizer (phase 2), a standardized extract of the common white kidney bean (Phaseolus vulgaris). International Journal of Toxicology, 25(5), 361–371. https://doi.org/10.1080/10915806.2006.10600846229

Chokshi, D. (2007). Subchronic oral toxicity of a standardized white kidney bean (Phaseolus vulgaris) extract in rats. Food and Chemical Toxicology, 45(1), 32–40. https://doi.org/10.1016/j.fct.2006.06.021

Chrispeels, M. J., & Raikhel, N. V. (1991). Lectins, lectin genes, and their role in plant defense. The Plant Cell, 3(1), 1–9.

Collins, C. L., Eason, P. J., Dunshea, F. R., Higgins, T. J. V., & King, R. H. (2006). Starch but not protein digestibility is altered in pigs fed transgenic peas containing α-amylase inhibitor. Journal of the Science of Food and Agriculture, 86(12), 1894–1899. https://doi.org/10.1002/jsfa.2551

Conlon, M. A., & Bird, A. R. (2015). The impact of diet and lifestyle on gut microbiota and human health. Nutrients, 7(1), 17–44. https://doi.org/10.3390/nu70100017

David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E., … Turnbaugh, P. J. (2014). Diet rapidly and reproducibly alters the human gut microbiome. Nature, 505(7484), 559–563. https://doi.org/10.1038/nature12820

de Moya, C. C., Grant, G., Frühbeck, G., Urdaneta, E., García, M., Marzo, F., & Santidrán, S. (2003). Local (gut) and systemic metabolism of rats is altered by consumption of raw bean (Phaseolus vulgaris L. var. atropurpurea). British Journal of Nutrition, 89(3), 311–318. https://doi.org/10.1079/bjn2002777

de Sales, P. M., de Souza, P. M., Simeoni, L. A., de Magalhães, P. O., & Silveira, D. (2012). α-Amylase inhibitors: A review of raw material and isolated compounds from plant source. Journal of Pharmacy and Pharmaceutical Sciences, 15(1), 141–183. https://doi.org/10.18433/J3553K

Dias, D. M., Kolba, N., Hart, J. J., Ma, M., Sha, S. T., Lakshmanan, N., … Tako, E. (2019). Soluble extracts from carioca beans (Phaseolus vulgaris L.) affect the gut microbiota and iron reduced brush border membrane protein expression in vivo (Gallus gallus). Food Research International, 123, 172–180. https://doi.org/10.1016/j.foodres.2019.04.060

Dubois, M., Gilles, K. A., Hamilton, J. K., Rebers, P. A., & Smith, F. (1956). Colorimetric method for determination of sugars and related substances. Analytical Chemistry (Washington, DC, United States), 28, 350–356.

Fantini, N., Cabras, C., Lobina, C., Colombo, G., Gessa, G. L., Riva, A., … Chrispeels, M. J., & Raikhel, N. V. (1991). Lectins, lectin genes, and their role in crop protection. The Plant Cell, 3(1), 1–9.

Franco, O. L., Rigden, D. J., Melo, F. R., & Grossi-de-Sá, M. F. (2002). High-carbohydrate, high-fiber diets increase fermentable carbohydrates by the human gut microbiota. Nutrients, 4(1), 26–36. https://doi.org/10.3390/nu40100026

Fukagawa, N. K., Anderson, J. W., Hageman, G., Young, V. R., & Minaker, K. L. (1990). High-carbohydrate, high-fiber diets increase peripheral insulin sensitivity in healthy young and old adults. The American Journal of Clinical Nutrition, 52(3), 524–528. https://doi.org/10.1093/ajcn/52.3.524

Ghorbani, F., Sadeghi, M., Aghaei, A., Ghahghaei, A., Jalili, C., & Khodarahimi, R. (2018). Study of α-amylase inhibitors among different bean cultivars and evaluation of their effectiveness compared with a commercial product using in vitro/in vivo experimental systems. Journal of Research in Medical and Dental Science, 6(1), 381–391. https://doi.org/10.5455/jrmds.20186162

Gibbs, B. F., & Alli, I. (1998). Characterization of a purified α-amylase inhibitor from white kidney beans (Phaseolus vulgaris). Food Research International, 31(3), 217–225. https://doi.org/10.1016/S0963-9969(98)00074-X

Gomes Mariana, J. C., da Silva, J. S., Assis, A., de Meija, E. G., Mantovani, H. C., & Martino, H. S. D. (2021). Common bean (Phaseolus vulgaris L.) flour can improve the gut microbiota composition and function in mice fed a high-fat diet. Current Developments in Nutrition, 5(Suppl. 2), 1159. https://doi.org/10.1039/cdn/nzab054_014

Grant, G., Dorward, P. M., Buchanan, W. C., Armour, J. C., & Pusztai, A. (1995). Consumption of diets containing raw soya beans (Glycine max), kidney beans (Phaseolus vulgaris), cowpeas (Vigna unguiculata) or lupin seeds (Lupinus angustifolius) by rats for up to 700 days: Effects on body composition and organ weights. The British Journal of Nutrition, 73(1), 17–29.

Grant, G., More, L. J., McKenzie, N. H., Stewart, J. C., & Pusztai, A. (1983). A survey of the nutritional and haemaggulitation properties of legume seeds generally available in the UK. British Journal of Nutrition, 50(2), 207–214. https://doi.org/10.1079/bjn19830090

Grossi de Sa, M. F., Mirkov, T. E., Ishimoto, M., Colucci, G., Bateman, K. S., & Chrispeels, M. J. (1997). Molecular characterization of a bean alpha-amylase inhibitor that inhibits the alpha-amylase of the Mexican bean weevil Zabrottes subfuscatus. Planta, 203(3), 295–303. https://doi.org/10.1007/s004250050195

Grube, B., Chong, W. F., Chong, P. W., & Riede, L. (2014). Weight reduction and maintenance with iQP-PV-101: A 12-week randomized controlled study with a 24-week open label period. Obesity, 22(3), 645–651. https://doi.org/10.1002/oby.20577

Hamelryck, T. W., Dao-Thi, M.-H., Poortmans, F., Chrispeels, M. J., Wyns, L., & Loris, R. (1996). The crystallographic structure of phytomoegglin-L. Journal of Biological Chemistry, 271(34), 20479–20485.

Harikumar, K. B., Jesil, A. M., Sabu, M. C., Kuttan, R., Aranjani, J., Mc, S., & Kuttan, R. (2005). A preliminary assessment of the acute and subchronic toxicity profile of phase 2: An α-amylase inhibitor. International Journal of Toxicology, 24(2), 95–102. https://doi.org/10.1080/1050159050036364

Harris, H. C., Edwards, C. A., & Morrison, D. J. (2017). Impact of glycosidic bond configuration on short chain fatty acid production from model fermentable carbohydrates by the human gut microbiota. Nutrients, 9(1), 25. https://doi.org/10.3390/nu9010026

Hasegawa, K., Kubota, M., & Matsuura, Y. (1999). Roles of catalytic residues in α-amylases as evidenced by the structures of the product-complexed mutants of a maltotetraose-forming amylase. Protein Engineering, 12(10), 819–824. https://doi.org/10.1093/protein/12.10.819

Hoffman, L. M., & Donaldson, D. D. (1985). Characterization of two Phaseolus vulgaris phytommeagglutinins genes closely linked on the chromosome. The EMBO Journal, 4(4), 883–889.

Hoffman, L. M., Ma, Y., & Barker, R. F. (1982). Molecular cloning of Phaseolus vulgaris lectin mRNA and use of cDNA as a probe to estimate lectin transcript levels in various tissues. Nucleic Acids Research, 10(23), 7819–7828.

Hollenbeck, C. B., Coulston, A. M., Quan, R., Becker, T. R., Vreman, H. J., Stevenson, D. K., & Reaven, G. M. (1983). Effects of a commercial starch blocker preparation on carbohydrate digestion and absorption: In vivo and in vitro studies. The American Journal of Clinical Nutrition, 38(4), 498–503. https://doi.org/10.1093/ajcn/38.4.498

Ishimoto, M., Suzuki, K., Iwana, M., Kikuchi, F., & Kitamura, K. (1995). Roles of catalytic residues in α-amylases as evidenced by the structures of the product-complexed mutants of a maltotetraose-forming amylase. Protein Engineering, 12(10), 819–824. https://doi.org/10.1093/protein/12.10.819

Izzo, A. A., Hoon-Kim, S., Radhakrishnan, R., & Williamson, E. M. (2016). A critical approach to evaluating clinical efficacy, adverse events and drug interactions of herbal remedies. Phytotherapy Research, 30(5), 691–700. https://doi.org/10.1002/ptr.5591
Rodhouse, J. C., Haugh, C. A., Roberts, D., & Gilbert, R. J. (1990). Red kidney bean poisoning in the UK: An analysis of 50 suspected incidents. London: Academic Press.

Richardson, M. (1991). Seed storage proteins: The enzyme inhibitors. In Richardson, M. (Ed.), Methods in Plant Biochemistry, (vol. 5, 209–305). London: Academic Press.

Rodhouse, J. C., Haugh, C. A., Roberts, D., & Gilbert, R. J. (1990). Red kidney bean poisoning in the UK: An analysis of 50 suspected incidents between 1976 and 1989. Epidemiology and Infection, 105(3), 485–491. https://doi.org/10.1017/S095026880004810X

Santimone, M., Koukiekolo, R., Moreau, Y., Le Berre, V., Rougé, P., Marchis-Mouren, G., & Desseaux, V. (2004). Porcine pancreatic α-amylase inhibition by the kidney bean (Phaseolus vulgaris) inhibitor (α-AI) and structural changes in the α-amylase inhibitor complex. Biochimica et Biophysica Acta - Proteins and Proteomics, 169(2), 181–190. https://doi.org/10.1016/j.bbapap.2003.11.001

Schneeman, B. O., Inman, M. D., & Stern, J. S. (1983). Pancreatic enzyme activity in obese and lean Zucker rats: A developmental study. The Journal of Nutrition, 113(4), 921–925. https://doi.org/10.1093/jn/113.4.921

Schroeder, H. E., Gollasch, S., Moore, A., Tabe, L. M., Craig, S., Hardie, D. C., Higgins, T. J. V. (1995). Bean [alpha]-amylase inhibitor confers resistance to the pea weevil (Bruchus pisorum) in transgenic peas (Pisum sativum L.). Plant Physiology, 107(4), 1239–1239. https://doi.org/10.1104/pp.107.4.1239

Shi, Z., Zhu, Y., Teng, C., Yao, Y., Ren, G., & Richel, A. (2020). Anti-obesity effects of α-amylase inhibitor enriched-extract from white common beans (Phaseolus vulgaris L.) associated with the modulation of gut microbiota composition in high-fat diet-induced obese rats. Food and Function, 11(2), 1624–1634. https://doi.org/10.1039/c9fo01813a

Song, H., Han, W., Yan, F., Xu, D., Chu, Q., & Zheng, X. (2016). Dietary Phaseolus vulgaris extract alleviated diet-induced obesity, insulin resistance and hepatic steatosis and alters gut microbiota composition in mice. Journal of Functional Foods, 20, 236–244. https://doi.org/10.1016/j.jff.2015.10.022

Spadafranca, A., Rinelli, S., Riva, A., Morazzoni, P., Magni, P., Bertoli, S., & Battezzati, A. (2013). Phaseolus vulgaris extract affects glycemic and appetite control in healthy human subjects. British Journal of Nutrition, 109(10), 1789–1795. https://doi.org/10.1017/S0007114512003741

Sparvoli, F., Giordano, S., Corneli, E., Avite, E., Giuberti, G., Luongo, D., & Predieri, S. (2021). Sensory characteristics and nutritional quality of food products made with a biofortified and lectin free common bean (Phaseolus vulgaris L.) flour. Nutrients, 13(12), 4517. https://doi.org/10.3390/nu13124517

Sumitani, J.-I., Tsujimoto, Y., Kawaguchi, T., & Arai, M. (2000). Cloning and secretive expression of the gene encoding the proteinaceous α-amylase inhibitor protein from Strepomyces coeruleorubius. Journal of Biochemistry and Biotechnology, 90(2), 214–216.

Sun, L., Warren, F. J., & Gidley, M. J. (2019). Natural products for glycaemic control: Polyphenols as inhibitors of alpha-amylase. Trends in Food Science and Technology, 91(7), 262–273. https://doi.org/10.1016/j.tifs.2019.07.009

Suzuki, K., Ishimoto, M., & Kitamura, K. (1994). cDNA sequence and deduced primary structure of an α-amylase inhibitor from a bruchid-resistant wild common bean. Biochimica et Biophysica Acta (BBA)-Protein Structure and Molecular Enzymology, 1206(2), 289–291.

Tangphantsomrung, S., Nacsonie, M., Thammarongtham, C., & Narangajavan, J. (2005). Isolation and characterization of an α-amylase gene in cassava (Manihot esculenta). Plant Physiology and Biochemistry, 43(9), 821–827. https://doi.org/10.1016/j.plaphy.2005.07.014

Tarocco-Haraldi, K. W., Hardianti, M. S., Sinorita, H., & Aryanudo, T. (2021). Obesity, leptin, and deregulation of microRNA in lipid metabolisms: Their contribution to breast cancer prognosis. Diabetology and Metabolic Syndrome, 13(1), 10. https://doi.org/10.1186/s13098-020-00621-4

The European Association for the Study of Obesity. OBESEITY STATISTICS. (2021). Retrieved from https://easo.org/media-portal/statistics/#:~:text=Overweight%20and%20obesity%20are%20the%20attributable%20to%20overweight%20and%20obesity,

Thom, E. (2000). A randomized, double-blind, placebo-controlled trial of a new weight-reducing agent of natural origin. The Journal of International Medical Research, 28(5), 229–233. https://doi.org/10.1177/147323000002800505

Thompson, L. U., Rea, R. L., & Jenkins, D. J. A. (1983). Effect of heat processing on hemagglutinin activity in red kidney beans. Journal of Food Science, 48(1), 235–236. https://doi.org/10.1111/j.1156-2621.1983.tb14831.x

Tormo, M. A., Gil-Exiojo, I., de Tejada, A. R., & Campillo, J. E. (2004). Hypoglycaemic and anorexigenic activities of an α-amylase inhibitor from white kidney beans (Phaseolus vulgaris) in Wistar rats. British Journal of Nutrition, 92(5), 785–790. https://doi.org/10.1079/bjn20041260

Tormo, M. A., Gil-Exiojo, I., de Tejada, A. R., & Campillo, J. E. (2006). White bean amylase inhibitor administered orally reduces glycaemia in type 2 diabetic rats. British Journal of Nutrition, 96(3), 539–544. https://doi.org/10.1079/BJN20061836

Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006). An obesity-associated gut microbiome with increased capacity for energy harvest. Nature, 444(7122), 1022–1031. https://doi.org/10.1038/nature05414

Udani, J., Hardy, M., & Kavoussi, B. (2007). Dietary supplement carbohydrates: Their contribution to breast cancer prognosis. British Journal of Nutrition, 97(14), 1627–1630. https://doi.org/10.1017/S0007114507007982

Udani, J., Hardy, M., & Madsen, D. C. (2004). Blocking carbohydrate absorption and weight loss: A clinical trial using phase 2 brand proprietary fractionated white bean extract. Alternative Medicine Review: A Journal of Clinical Therapeutic, 9(1), 63–69.

Udani, J., & Singh, B. B. (2007). Blocking carbohydrate absorption and weight loss: A clinical trial using a proprietary fractionated white bean extract. Alternative Therapies in Health and Medicine, 13(4), 32–37. Retrieved from file:///C:/Users/Stefania/Desktop/Bibliografia/biblio per parte medica/medicine/urbanudani2004 blocking carbohydrate absorption.pdf

Udani, J., Tan, O., & Molina, J. (2018). Systematic review and meta-analysis of a proprietary alpha-amylase inhibitor from white bean (Phaseolus vulgaris L.) on weight and fat loss in humans. Food, 7(4), 63. https://doi.org/10.3390/foods7040063

Udani, J. K., Singh, B. B., Barrett, M. L., & Preuss, H. G. (2009). Lowering the glycemic index of white bread using a white bean extract. Nutrition Journal, 8(1), 1–5. https://doi.org/10.1186/1475-2891-8-52
Valencia, A., Bustillo, A. E., Ossa, G. E., & Chrispeels, M. J. (2000). α-Amylases of the coffee berry borer (Hypothenemus hampei) and their inhibition by two plant amylase inhibitors. *Insect Biochemistry and Molecular Biology*, 30(3), 207–213. https://doi.org/10.1016/S0965-1748(99)00115-0

Vinson, J. A., Al Kharrat, H., & Shuta, D. (2009). Investigation of an amylase inhibitor on human glucose absorption after starch consumption. *The Open Nutraceuticals Journal*, 2(1), 88–91. https://doi.org/10.2174/138920009787522133

Wang, Guo, C., Xing, Z., Li, M., Yang, H., Zhang, Y., … Mi, S. (2021). Dietary intervention with α-amylase inhibitor in white kidney beans added yogurt modulated gut microbiota to adjust blood glucose in mice. *Frontiers in Nutrition*, 8, 664976. https://doi.org/10.3389/fnut.2021.664976

Wang, H. H., Chen, C. L., Jeng, T. L., & Sung, J. M. (2011). Comparisons of α-amylase inhibitors from seeds of common bean mutants extracted through three phase partitioning. *Food Chemistry*, 128(4), 1066–1071. https://doi.org/10.1016/j.foodchem.2011.04.015

Wang, S., Chen, L., Yang, H., Gu, J., Wang, J., & Ren, F. (2020). Regular intake of white kidney beans extract (Phaseolus vulgaris L.) induces weight loss compared to placebo in obese human subjects. *Food Science and Nutrition*, 8(3), 1315–1324. https://doi.org/10.1002/fsn3.1299

Whitcomb, D. C., & Lowe, M. E. (2007). Human pancreatic digestive enzymes. *Digestive Diseases and Sciences*, 52(1), 1–17. https://doi.org/10.1007/s10620-006-9589-z

WHO. Obesity and overweight. (2021). Retrieved from https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

Worku, A., & Sahu, O. (2017). Significance of fermentation process on biochemical properties of Phaseolus vulgaris (red beans). *Biotechnology Reports*, 16, 5–11. https://doi.org/10.1016/j.btre.2017.09.001

Wu, X., Xu, X., Shen, J., Perricone, N. V., & Preuss, H. G. (2010). Enhanced weight loss from a dietary supplement containing standardized Phaseolus vulgaris extract in overweight men and women. *Journal of Applied Research*, 10(2), 73–79. Retrieved from https://www.jmlappliedresearch.com/articles/Vol10Iss2/Vol10%20Iss2Wu.pdf

Yamada, J., Yamamoto, T., & Yamaguchi, H. (2007). Effects of combination of functional food materials on body weight, body fat percentage, serum triglyceride and blood glucose. Retrieved from http://www.phase2info.com/pdf/Phase2_Study15.pdf

Yamada, T., Hattori, K., & Ishimoto, M. (2001). Purification and characterization of two α-amylase inhibitors from seeds of tepary bean (Phaseolus acutifolius a. gray). *Phytochemistry*, 58(1), 59–66. https://doi.org/10.1016/S0031-9422(01)00178-9

Yamagishi, S., Matsu, T., Ueda, S., Fukami, K., & Okuda, S. (2009). Clinical utility of acarbose, an alpha-glucosidase inhibitor in cardiometabolic disorders. *Current Drug Metabolism*, 10(2), 159–163. https://doi.org/10.2174/138920009787522133

Yamaguchi, H. (1991). Isolation and characterization of the subunits of Phaseolus vulgaris α-amylase inhibitor. *The Journal of Biochemistry*, 110(5), 785–789.

Yamaguchi, H., Funaoaka, H., & Iwamoto, H. (1992). Structures of sugar chains of the subunits of an α-amylase inhibitor from Phaseolus vulgaris white kidney beans. *The Journal of Biochemistry*, 111(3), 388–395.

Yao, Y., Hu, Y., Zhu, Y., Gao, Y., & Ren, G. (2016). Comparisons of phaseolin type and α-amylase inhibitor in common bean (Phaseolus vulgaris L.) in China. *Crop Journal*, 4(1), 68–72. https://doi.org/10.1016/j.cj.2015.09.002

Yoon, S. H., Bruce Fulton, D., & Robyt, J. F. (2007). Formation of covalent β-linked carbohydrate-enzyme intermediates during the reactions catalyzed by α-amylases. *Carbohydrate Research*, 342(1), 55–64. https://doi.org/10.1016/j.carres.2006.10.028

Zhang, S., Cavender, G. A., & Allen, J. C. (2020). Max bloc® carb blocker from Phaseolus vulgaris with ultra-high α-amylase inhibitory activity for glycemic control and weight management. *Journal of Nutrition & Food Sciences*, 2(1), 1–8.

Zulkarnain, R., Setiawati, A., & Setiabudy, R. (2009). Effect of a combination of Phaseolus vulgaris L. extract and acarbose on postprandial glucose level after cooked rice intake in healthy volunteers. *Medical Journal of Indonesia*, 18(1), 25–30. https://doi.org/10.13181/mji.v18i1.335

---

**How to cite this article**: Peddio, S., Padiglia, A., Cannea, F. B., Crnjar, R., Zam, W., Sharifi-Rad, J., Rescigno, A., & Zucca, P. (2022). Common bean (Phaseolus vulgaris L.) α-amylase inhibitors as safe nutraceutical strategy against diabetes and obesity: An update review. *Phytotherapy Research*, 36(7), 2803–2823. https://doi.org/10.1002/ptr.7480